The main target of CAR-T therapy in MM is BCMA (CD269/TNFRSF17), which belongs to the tumor necrosis factor (TNF) superfamily and is essential for plasma cell differentiation and long-term survival [18, 19]. The gene discussed is TNF; the disease is Miyoshi myopathy.